Fulcrum Therapeutics (FULC) Earnings Date, Estimates & Call Transcripts → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free fulc Stock Alerts $7.06 -0.09 (-1.26%) (As of 04/18/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 20EstimatedActual EPS (Feb. 27) -$0.40 Beat By $0.04 Consensus EPS (Feb. 27) -$0.44 Get Fulcrum Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for FULC and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueFULC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.FULC Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. Fulcrum Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.46)($0.40)($0.43)Q2 20242($0.45)($0.40)($0.43)Q3 20242($0.44)($0.41)($0.43)Q4 20242($0.43)($0.41)($0.42)FY 20248($1.78)($1.62)($1.70)FULC Earnings Date and InformationFulcrum Therapeutics last posted its quarterly earnings data on February 27th, 2024. The reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04. The firm earned $0.87 million during the quarter, compared to analyst estimates of $0.65 million. Fulcrum Therapeutics has generated ($1.58) earnings per share over the last year (($1.58) diluted earnings per share). Earnings for Fulcrum Therapeutics are expected to grow in the coming year, from ($1.76) to ($1.74) per share. Fulcrum Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off prior year's report dates.Read More Fulcrum Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/20/2024Estimated)------- 2/27/2024Q4 2023($0.44)($0.40)+$0.04($0.40)$0.65 million$0.87 million11/7/2023Q3 2023($0.44)($0.39)+$0.05($0.39)$1.81 million$0.76 million8/3/2023Q2 2023($0.44)($0.38)+$0.06($0.38)$1.60 million$0.88 million5/15/2023Q1 2023($0.47)($0.41)+$0.06($0.41)$1.73 million$0.30 million3/9/2023Q4 2022($0.49)($0.50)($0.01)($0.50)$1.92 million$0.69 million11/8/2022Q3 2022($0.62)($0.50)+$0.12($0.49)$2.19 million$1.18 million Get the Latest News and Ratings for FULC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/11/2022Q2 2022($0.66)($0.83)($0.17)($0.83)$2.65 million$1.88 million5/9/2022Q1 2022($0.63)($0.64)($0.01)($0.64)$3.46 million$2.59 million3/3/2022Q4 2021($0.65)($0.58)+$0.07($0.58)$4.00 million$5.06 million 11/4/2021Q3 2021($0.64)($0.57)+$0.07($0.57)$2.94 million$4.94 million 8/10/2021Q2 2021($0.65)($0.60)+$0.05($0.60)$2.69 million$4.38 million 5/6/2021Q1 2021($0.66)($0.54)+$0.12($0.54)$2.18 million$4.79 million Fulcrum Therapeutics Earnings - Frequently Asked Questions When is Fulcrum Therapeutics's earnings date? Fulcrum Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off last year's report dates. Learn more on FULC's earnings history. Did Fulcrum Therapeutics beat their earnings estimates last quarter? In the previous quarter, Fulcrum Therapeutics (NASDAQ:FULC) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.04. Learn more on analysts' earnings estimate vs. FULC's actual earnings. How much revenue does Fulcrum Therapeutics generate each year? Fulcrum Therapeutics (NASDAQ:FULC) has a recorded annual revenue of $2.81 million. How much profit does Fulcrum Therapeutics generate each year? Fulcrum Therapeutics (NASDAQ:FULC) has a recorded net income of -$97.33 million. FULC has generated -$1.58 earnings per share over the last four quarters. What is Fulcrum Therapeutics's EPS forecast for next year? Fulcrum Therapeutics's earnings are expected to grow from ($1.76) per share to ($1.74) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Travere Therapeutics Earnings Neurogene Earnings IGM Biosciences Earnings Lexicon Pharmaceuticals Earnings Arbutus Biopharma Earnings KalVista Pharmaceuticals Earnings Mersana Therapeutics Earnings Revance Therapeutics Earnings Annexon Earnings AnaptysBio Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: CSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted Applied Optoelectronics earnings dumper, pain now for gain later?Is Roku worth a second look after the earnings panic selloff? This page (NASDAQ:FULC) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving TrendsHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.